The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology;
The Russian National Research Medical University named after N.I. Pirogov

Petunina V.V.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology;
The Russian National Research Medical University named after N.I. Pirogov

Zhukova O.V.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology, Department of Healthcare;
Peoples’ Friendship University of Russia

Avanesova V.I.

The Russian National Research Medical University named after N.I. Pirogov

Tkachenko S.B.

Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation

JAK-STAT pathway in the vitiligo pathogenesis and therapy with Janus kinase inhibitors

Authors:

Potekaev N.N., Petunina V.V., Zhukova O.V., Avanesova V.I., Tkachenko S.B.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2022;21(1): 8‑14

DOI: 10.17116/klinderma2022210118

Read: 4200 times

Download PDF (RU)
Contact the author
Table of contents

JAK-STAT PATHWAY IN THE VITILIGO PATHOGENESIS AND THERAPY WITH JANUS KINASE INHIBITORS
JAK-STAT PATHWAY IN THE VITILIGO PATHOGENESIS AND THERAPY WITH JANUS KINASE INHIBITORS

To cite this article:

Potekaev NN, Petunina VV, Zhukova OV, Avanesova VI, Tkachenko SB. JAK-STAT pathway in the vitiligo pathogenesis and therapy with Janus kinase inhibitors. Russian Journal of Clinical Dermatology and Venereology. 2022;21(1):8‑14. (In Russ.)
https://doi.org/10.17116/klinderma2022210118

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Study of the role of inte­rleukin-1β in blood serum in patients with acne. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):421-424
The effect of the iron III poly­saccharide complex use on the cyto­kines, natriuretic peptide and erythropoietin levels in patients with chro­nic heart failure acco­mpanied with anemia. Russian Journal of Preventive Medi­cine. 2025;(3):80-86
Study of serum cyto­kine concentration in primary patients with gastric cancer. P.A. Herzen Journal of Onco­logy. 2025;(2):25-29
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Asso­ciations of gene­tic poly­morphisms in key inflammatory response genes with the risk of chro­nic apical periodontitis deve­lopment. Russian Journal of Stomatology. 2025;(2):52-56
Proinflammatory cyto­kines — as a marker of the effe­ctiveness of neuroprotection in children with peri­natal nervous system damage. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):62-66
Myokines — the cardiometabolic risk pote­ntial biomarkers. Russian Journal of Preventive Medi­cine. 2025;(7):119-126
The role of neuroinflammation in the deve­lopment of seizure acti­vity and auto­nomic diso­rders in patients with epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):50-58
Biomarkers in tear fluid in uveitis. Russian Annals of Ophthalmology. 2025;(4):88-95
Basic and complex therapy of non-segmental viti­ligo with como­rbid anxiety and anxiety-depressive adju­stment diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):51-58
Abstract:

This article is a literature review consisting of two topical units. The first part of the article addresses the fundamental concepts and mechanisms of the JAK-STAT pathway. Currently, understanding the drugs’ mechanisms of action based on the Janus kinase inhibition principle is crucial. According to international studies, an increasing number of conditions with an autoimmune component are showing good clinical response. Thus, the use of Janus kinase inhibition in dermatovenerology is considered promising, for example, in vitiligo, alopecia, atopic dermatitis. The second part of the is a literature review with analysis of data on the effects and clinical outcomes in patients with vitiligo treated with these drugs.Historical cases of the first patients treated with Janus kinase inhibitors initially used in rheumatoid arthritis patients are described. Adverse skin reactions were also addressed.A clinical case of vitiligo exacerbation that occurred during these drugs therapy and the analysis of possible cause-effect relations are presented. Known skin reactions in patients on long-term therapy are listed. The initial results of a phase II trial of selective Janus kinase inhibitors used in vitiligo patients are headlined.

Keywords:

vitiligo
Janus kinase inhibitors
JAK-STAT
(pSTAT)
pro-inflammatory proteins
cytokines
JAK1
JAK3
JAK2
vitiligo therapy
vitiligo pathogenesis
T-cells
melanogenesis
depigmentation
repigmentation
melanocyte
ritlecitinib
CXCL9
CXCL10

Authors:

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology;
The Russian National Research Medical University named after N.I. Pirogov

Petunina V.V.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology;
The Russian National Research Medical University named after N.I. Pirogov

Zhukova O.V.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology, Department of Healthcare;
Peoples’ Friendship University of Russia

Avanesova V.I.

The Russian National Research Medical University named after N.I. Pirogov

Tkachenko S.B.

Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation

Received:

29.04.2021

Accepted:

27.11.2021

Close metadata

References:

  1. O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(suppl 2)(0 2):ii111-115. PMID: 23532440; PMCID: PMC3616338. https://doi.org/10.1136/annrheumdis-2012-202576
  2. Aittomäki S, Pesu M. Therapeutic targeting of the Jak/STAT pathway. Basic Clin Pharmacol Toxicol. 2014;114(1):18-23. Epub 2013 Nov 15. PMID: 24164900. https://doi.org/10.1111/bcpt.12164
  3. Ghoreschi K, Laurence A, O’Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol. 2009;10(4):356-60. Epub 2009 Mar 19. PMID: 19295632; PMCID: PMC2758543. https://doi.org/10.1038/ni.1701
  4. O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311-328. PMID: 25587654; PMCID: PMC5634336. https://doi.org/10.1146/annurev-med-051113-024537
  5. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415-1421. PMID: 8197455. https://doi.org/10.1126/science.8197455
  6. Sideris N, Vakirlis E, Tsentemeidou A, Kourouklidou A, Ioannides D, Sotiriou E. Under Development JAK Inhibitors for Dermatologic Diseases. Mediterr J Rheumatol. 2020;31(1):137-144. Published 2020 Jun 11.  https://doi.org/10.31138/mjr.31.1.137
  7. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, O’Shea JJ, Leonard WJ. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995 Nov 3;270(5237):797-800. PMID: 7481768. https://doi.org/10.1126/science.270.5237.797
  8. Vijayakrishnan L, Venkataramanan R, Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci. 2011;32(1):25-34. Epub 2010 Dec 7. PMID: 21144599. https://doi.org/10.1016/j.tips.2010.10.004
  9. Hammarén HM, Virtanen AT, Raivola J, Silvennoinen O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2019;118:48-63. Epub 2018 May 21. PMID: 29685781. https://doi.org/10.1016/j.cyto.2018.03.041
  10. Virtanen T, Anniina et al. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 2019;33(1):15-32.  https://doi.org/10.1007/s40259-019-00333-w
  11. Haan C, Rolvering C, Raulf F, Kapp M, Drückes P, Thoma G, Behrmann I, Zerwes HG. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chem Biol. 2011;18(3):314-323. PMID: 21439476. https://doi.org/10.1016/j.chembiol.2011.01.012
  12. Villarino AV, Kanno Y, Ferdinand JR, O’Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol. 2015;194(1):21-27. PMID: 25527793; PMCID: PMC4524500. https://doi.org/10.4049/jimmunol.1401867
  13. Solimani F, Meier K, Ghoreschi K. Emerging Topical and Systemic JAK Inhibitors in Dermatology. Front Immunol. 2019;10:2847. Published 2019 Dec 3.  https://doi.org/10.3389/fimmu.2019.02847
  14. Damsky, William, and Brett A King. JAK inhibitors in dermatology: The promise of a new drug class. Journal of the American Academy of Dermatology. 2017;76(4):736-744.  https://doi.org/10.1016/j.jaad.2016.12.005
  15. Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-1212. Epub 2012 Mar 27. PMID: 22458952. https://doi.org/10.1111/j.1365-4632.2011.05377.x
  16. Malhotra N, Dytoc M. The pathogenesis of vitiligo. J Cutan Med Surg. 2013;17(3):153-172. PMID: 23673299. https://doi.org/10.2310/7750.2012.12005
  17. Boniface K, Seneschal J, Picardo M, Taïeb A. Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy. Clin Rev Allergy Immunol. 2018; 54(1):52-67. PMID: 28685247. https://doi.org/10.1007/s12016-017-8622-7
  18. Kasumagic-Halilovic E, Ovcina-Kurtovic N, Soskic S, et al. Serum levels of interleukin-2 and interleukin-2 soluble receptor in patients with vitiligo. Br J Med Med Res. 2016;13(10):1-7. 
  19. Shi YL, Li K, Hamzavi I, et al. Elevated circulating soluble interleukin-2 receptor in patients with non-segmental vitiligo in North American. J Dermatol Sci. 2013;71(3):212-214. 
  20. Honda Y, Okubo Y, Koga M. Relationship between levels of soluble interleukin-2 receptors and the types and activity of vitiligo. J Dermatol. 1997; 24(9):561-563. 
  21. Wang XX, Wang QQ, Wu JQ, Jiang M, Chen L, Zhang CF, Xiang LH. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol. 2016;174(6): 1318-1326. Epub 2016 May 4. PMID: 26801009. https://doi.org/10.1111/bjd.14416
  22. Relke N, Gooderham M. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature. J Cutan Med Surg. 2019;23(3):298-306. Epub 2019 Mar 22. PMID: 30902022. https://doi.org/10.1177/1203475419833609
  23. Lee AY. Role of keratinocytes in the development of vitiligo. Ann Dermatol. 2012;24(2):115-125. Epub 2012 Apr 26. PMID: 22577260; PMCID: PMC3346900. https://doi.org/10.5021/ad.2012.24.2.115
  24. Rezk AF, Kemp DM, El-Domyati M, El-Din WH, Lee JB, Uitto J, Igoucheva O, Alexeev V. Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression. J Invest Dermatol. 2017;137(5):1126-1134. Epub 2017 Jan 26. PMID: 28132854. https://doi.org/10.1016/j.jid.2016.12.028
  25. Harris JE. Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev. 2016;269(1):11-25. PMID: 26683142; PMCID: PMC4685729. https://doi.org/10.1111/imr.12369
  26. Wang XX, Wang QQ, Wu JQ, Jiang M, Chen L, Zhang CF, Xiang LH. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol. 2016;174(6): 1318-1326. Epub 2016 May 4. PMID: 26801009. https://doi.org/10.1111/bjd.14416
  27. Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, Zhou Y, Deng A, Hunter CA, Luster AD, Harris JE. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6(223):223ra23. PMID: 24523323; PMCID: PMC4086941. https://doi.org/10.1126/scitranslmed.3007811
  28. Rashighi M, Harris JE. Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med. 2015;3(21):343. PMID: 26734651; PMCID: PMC4690998. https://doi.org/10.3978/j.issn.2305-5839.2015.11.36
  29. Richmond JM, Bangari DS, Essien KI, Currimbhoy SD, Groom JR, Pandya AG, Youd ME, Luster AD, Harris JE. Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease. J Invest Dermatol. 2017;137(2):350-358. Epub 2016 Sep 26. PMID: 27686391; PMCID: PMC5258673. https://doi.org/10.1016/j.jid.2016.09.016
  30. Van den Boorn JG, Konijnenberg D, Dellemijn TA, van der Veen JP, Bos JD, Melief CJ, Vyth-Dreese FA, Luiten RM. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol. 2009;129(9):2220-2232. Epub 2009 Feb 26. PMID: 19242513. https://doi.org/10.1038/jid.2009.32
  31. Moretti S, Fabbri P, Baroni G, Berti S, Bani D, Berti E, Nassini R, Lotti T, Massi D. Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol Histopathol. 2009;24(7):849-857. PMID: 19475531. https://doi.org/10.14670/HH-24.849
  32. Wang S, Zhou M, Lin F, Liu D, Hong W, Lu L, Zhu Y, Xu A. Interferon-γ induces senescence in normal human melanocytes. PLoS One. 2014;9(3): e93232. PMID: 24681574; PMCID: PMC3969336. https://doi.org/10.1371/journal.pone.0093232
  33. Johnston JA, Kawamura M, Kirken RA, Chen YQ, Blake TB, Shibuya K, Ortaldo JR, McVicar DW, O’Shea JJ. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature. 1994;370(6485):151-153. PMID: 8022485. https://doi.org/10.1038/370151a0
  34. Müller M, Briscoe J, Laxton C, Guschin D, Ziemiecki A, Silvennoinen O, Harpur AG, Barbieri G, Witthuhn BA, Schindler C, et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature. 1993;366(6451):129-135. PMID: 8232552. https://doi.org/10.1038/366129a0
  35. https://clinicaltrials.gov/ct2/show/NCT03715829?term=Pfizer&cond=Vitiligo&draw=2&rank=1
  36. Craiglow BG, King BA. Tofacitinib Citrate for the Treatment of Vitiligo. JAMA Dermatology. 2015;151:1110-1112. PMID: 26107994.
  37. Kostovic K, Gulin SJ, Mokos ZB, Ceovic R. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology. Curr Med Chem. 2017;24:1158-1167. PMID: 28088907.
  38. Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016;74:370-371. PMID: 26685721.
  39. Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib — an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:318-328. PMID: 26966791.
  40. https://escholarship.org/uc/item/1hk2x4j5
  41. Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: A systematic review. J Am Acad Dermatol. 2017;76:745-753.e19. PMID: 28169015.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.